A phase II double-blind, randomized, placebo-controlled study to evaluate the antiretroviral effect of immunization with the MRK Ad5 HIV-1 Gag vaccine [HIV vaccine] in HIV-1 infected individuals who interrupt antiretroviral therapy.

Trial Profile

A phase II double-blind, randomized, placebo-controlled study to evaluate the antiretroviral effect of immunization with the MRK Ad5 HIV-1 Gag vaccine [HIV vaccine] in HIV-1 infected individuals who interrupt antiretroviral therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Sep 2014

At a glance

  • Drugs V 520 (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 May 2012 Actual end date changed from Jun 2006 to May 2011 as reported by ClinicalTrials.gov.
    • 05 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Sep 2010 Results were published in the Journal of Infectious Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top